1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Endothelial Dysfunction - Pipeline Review, H1 2014

Endothelial Dysfunction - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 40 pages

Endothelial Dysfunction - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Endothelial Dysfunction - Pipeline Review, H1 2014’, provides an overview of the Endothelial Dysfunction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endothelial Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endothelial Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endothelial Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endothelial Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endothelial Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endothelial Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Endothelial Dysfunction - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Endothelial Dysfunction Overview 6
Therapeutics Development 7
Pipeline Products for Endothelial Dysfunction - Overview 7
Pipeline Products for Endothelial Dysfunction - Comparative Analysis 8
Endothelial Dysfunction - Therapeutics under Development by Companies 9
Endothelial Dysfunction - Therapeutics under Investigation by Universities/Institutes 10
Endothelial Dysfunction - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Endothelial Dysfunction - Products under Development by Companies 13
Endothelial Dysfunction - Products under Investigation by Universities/Institutes 14
Endothelial Dysfunction - Companies Involved in Therapeutics Development 15
Johnson and Johnson 15
Chugai Pharmaceutical Co., Ltd. 16
Glucox Biotech AB 17
Stealth Peptides Inc. 18
Endothelial Dysfunction - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
MTP-131 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
maxacalcitol - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
S-adenosyl methionine - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Small Molecule To Inhibit NOX-4 For Endothelial Dysfunction - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
MC-1575 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Endothelial Dysfunction - Recent Pipeline Updates 35
Endothelial Dysfunction - Dormant Projects 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables

Number of Products under Development for Endothelial Dysfunction, H1 2014 7
Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Endothelial Dysfunction - Pipeline by Johnson and Johnson, H1 2014 15
Endothelial Dysfunction - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 16
Endothelial Dysfunction - Pipeline by Glucox Biotech AB, H1 2014 17
Endothelial Dysfunction - Pipeline by Stealth Peptides Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Endothelial Dysfunction Therapeutics - Recent Pipeline Updates, H1 2014 35
Endothelial Dysfunction - Dormant Projects, H1 2014 38

List of Figures

Number of Products under Development for Endothelial Dysfunction, H1 2014 7
Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.